Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

982.59 -19.72 (-1.97%)
Streaming Delayed Price Updated: 2:24 PM EDT, Sep 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
From argenx SE
Via GlobeNewswire
News headline image
argenx Reports First Quarter 2026 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at BofA Securities 2026 Health Care Conference
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
From argenx SE
Via GlobeNewswire
News headline image
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
From argenx SE
Via GlobeNewswire
News headline image
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story ↗
This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch ↗
Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
argenx announces Annual General Meeting of Shareholders on May 6, 2026
From argenx SE
Via GlobeNewswire
News headline image
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund ↗
RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal... 
Via Finterra
Topics Economy
News headline image
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗
Dianthus Therapeutics announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy program based on analysis of data from a part of... 
Via Stocktwits
News headline image
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
From argenx SE
Via GlobeNewswire
News headline image
Argenx (ARGX) 2026 Feature: The Anatomy of a Biotech Powerhouse Transitioning to Profitability
As of February 26, 2026, the biotechnology sector is witnessing a historic maturation. For years, the industry narrative was dominated by high-burn, pre-revenue innovators searching for a "blockbuster"... 
Via Finterra
Topics Earnings Economy Intellectual Property
News headline image
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at TD Cowen 46th Annual Healthcare Conference
From argenx SE
Via GlobeNewswire
News headline image
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
From argenx SE
Via GlobeNewswire
News headline image
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗
This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors. 
Via The Motley Fool
News headline image
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs. 
Via The Motley Fool
News headline image
Roivant Sciences (ROIV): Anatomy of a 15% Surge and the Future of the ‘Vant’ Model
As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a... 
Via Finterra
Topics ETFs Economy Initial Public Offering
News headline image
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
From argenx SE
Via GlobeNewswire
News headline image
argenx Highlights 2026 Strategic Priorities
From argenx SE
Via GlobeNewswire
News headline image
argenx to Present at 44th Annual J.P. Morgan Healthcare Conference
From argenx SE
Via GlobeNewswire
News headline image
argenx Announces Leadership Transition Marking Next Evolution of Growth
From argenx SE
Via GlobeNewswire
News headline image
Beyond the Bot: 2026 Marks the Great Rebalancing as Investors Pivot from AI Hype to Tangible Growth
As the opening bell rings on January 2, 2026, the financial landscape looks fundamentally different from the AI-crazed atmosphere of the previous two years. The "AI Infrastructure Fever" that dominated... 
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
The 2026 Horizon: Technical Breakouts Signal a Sustained Bull Run in AI and Energy
As the final trading bell of 2025 rings, the financial markets are closing the year on a high note, characterized by a series of powerful technical breakouts across several high-growth sectors. The S&P... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Biohaven Ltd. (BHVN): A High-Stakes Clinical Crossroad in Neuroscience and Immunology
As of December 26, 2025, Biohaven Ltd. (NYSE: BHVN) finds itself at a critical juncture. Once the darling of the biotech sector following a staggering $11.6 billion acquisition of its migraine... 
Via PredictStreet
Topics Economy Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.